Skip to main content
. 2019 Aug 13;21(11):2429–2439. doi: 10.1111/dom.13824

Table 1.

Demographic and baseline characteristics (safety set)

Placebo n = 60 Efpeglenatide 4 mg once weekly n = 59 Efpeglenatide 6 mg once weekly n = 59 Efpeglenatide 6 mg once every 2 wk n = 59 Efpeglenatide 8 mg once every 2 wk n = 58 All N = 295
Age, years 43.7 (11.8) 42.9 (12.1) 43.0 (13.0) 43.3 (12.5) 43.9 (9.2) 43.4 (11.7)
Female, n (%) 44 (73.3) 41 (69.5) 46 (78.0) 43 (72.9) 51 (87.9) 225 (76.3)
Race, n (%)
White 39 (65.0) 41 (69.5) 37 (62.7) 45 (76.3) 39 (67.2) 201 (68.1)
Black or African‐American 16 (26.7) 12 (20.3) 11 (18.6) 8 (13.6) 13 (22.4) 60 (20.3)
Asian 3 (5.0) 4 (6.8) 8 (13.6) 5 (8.5) 5 (8.6) 25 (8.5)
Other 2 (3.3) 2 (3.4) 3 (5.1) 1 (1.7) 1 (1.7) 9 (3.1)
Ethnicity, n (%)
Hispanic or Latino 7 (11.7) 4 (6.8) 10 (16.9) 7 (11.9) 6 (10.3) 34 (11.5)
Not Hispanic or Latino 53 (88.3) 55 (93.2) 49 (83.1) 52 (88.1) 52 (89.7) 261 (88.5)
Weight, kg 97.5 (12.1) 100.8 (19.3) 101.7 (19.4) 99.5 (18.4) 95.6 (13.3) 99.0 (16.8)
BMI, kg/m2 34.9 (3.2) 35.2 (4.5) 36.3 (4.4) 35.6 (4.8) 35.2 (3.9) 35.4 (4.2)
BMI 27 to <30 kg/m2, n (%) 2 (3.3) 5 (8.5) 3 (5.1) 2 (3.4) 3 (5.2) 15 (5.1)
BMI ≥30 kg/m2, n (%) 58 (96.7) 54 (91.5) 56 (94.9) 57 (96.6) 55 (94.8) 280 (94.9)
Waist circumference, cm
Women 107.0 (10.1) 107.1 (10.2) 110.5 (13.4) 106.8 (10.8) 108.7 (11.1) 108.1 (11.2)
n 44 41 46 43 51 225
Men 115.8 (9.7) 115.8 (14.3) 116.9 (11.9) 117.2 (11.3) 110.3 (10.3) 115.8 (11.7)
n 16 18 13 16 7 70
HbA1c, mmol/mol 36.4 (4.4) 36.1 (4.0) 35.3 (4.7) 36.9 (3.5) 35.9 (4.2) 36.1 (4.2)
HbA1c, % 5.5 (0.4) 5.5 (0.4) 5.4 (0.4) 5.5 (0.3) 5.4 (0.4) 5.5 (0.4)
FPG, mmol/L 5.3 (0.6) 5.2 (0.7) 5.3 (0.6) 5.4 (0.7) 5.3 (0.5) 5.3 (0.6)

Data are mean (SD) unless otherwise stated.

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin.